

HA330-II Disposable Hemoperfusion Cartridge Properties

Adsorbent Volume(mL)	330
Biocompatibility	Tested as required in ISO10993
Adsorbent Material	Double Cross-linked Styrene-divinylbenzene Copolymers
Housing Material	Polycarbonate
Sterilization Method	Irradiation Sterilization
Unit Package	285±2mm(L)*117±2mm(W)*108±2mm(H)

*Contraindications, Warnings and Precautions refer to Instructions For Use.

JAFRON - Global Manufacturer and Supplier of Adsorption Columns



Jafron Headquarters



CE



ISO 9001



EN ISO 13485

References

- [1] Hu, S., Gao, H., Liao, M. et al. (2008). Comparisons of effects of different types of physical artificial liver support system applied in treatment of patients with early stage of chronic severe hepatitis. *Chin J TCM WM Crit Care*, 15(2).
- [2] Li, M., Sun, J., Li, J., Shi, Z., Xu, J., Lu, B. et al. (2016). Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver. *Experimental and Therapeutic Medicine*, 12(6), 3873-3876.
- [3] Luo, L., Yuan, C., Zeng, W., Zhang, D. (2008). Treatment of severe hepatitis by HA neutral macroporous resin hemoperfusion: an analysis of 40 cases. *World Chinese Journal Of Digestology*, 16(22), 2533.
- [4] Wang, Z., Wang, Y., Wen, H., Wang, Y. (2003). Observation in vitro for the efficiency of resin hemoperfusion on severe hepatitis. *Chinese Journal of Blood Purification*, 2(1).
- [5] Sharma, D, Singh, O, Juneja, D, Goel, A, Garg, SK, Shekhar, S. (2018). Hepatitis a virus-induced severe hemolysis complicated by severe Glucose-6-Phosphate Dehydrogenase deficiency. *Indian J Crit Care Med*.

CY-HA330-II-01-10-2021-EN



Stock Abbreviation: JFSW
Stock Code: 300529

Remove Hepatic Toxins^[1-5]



HA330-II

HA330-II Disposable Hemoperfusion Cartridge

20 years in blood purification clinical practices
Widely used in more than 80 countries
More than 5 million treatments per year



JAFRON BIOMEDICAL CO., LTD.

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.
Tel: +86 (756) 3689708
E-mail: overseatrade@jafron.com
Website: www.jafron.com

(For Internal Use)

HA330-II hemoperfusion therapy can be used alone or in combination with other extracorporeal blood circulations, which provides a new therapy to reduce inflammatory mediators, toxins, bilirubin, etc. in **drug-induced hepatitis, hepatic failure, and their complications such as hepatic encephalopathy.**^[1-5]


Resin Adsorbent with Efficiency & Safety




- Large adsorptive surface area
- High mechanical strength of adsorbents
- Resin material with advanced coating technology
- Optimized fluid dynamic design
- Filter prevents particle detachment into human body

Therapy Operation Modes^A



✦ (1) Hemoperfusion (HP)



✦ (2) Double Plasma Molecular Adsorption System (DPMAS)



✦ (3) HP+HD/CRRT




HP+CRRT


^AFor detailed information, please visit www.jafron.com.

Improve Therapeutic Effect


✦ Clinical applications demonstrated that HA330-II could regulate the inflammatory mediators, ALT and AST levels, which indicated the improvement of liver function.^{[1][2][3][5]}




Serial ammonia, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase levels, and effects of HA330-II filters.



✦ Results indicated that HA330-II removed Bilirubin.^{[3][4]}



✦ Clinical application showed good biocompatibility, with little harm to blood component and few adverse reaction.^[2]



Note: Clinical practices should base on patients' situations and complications, to choose customized artificial liver support system.